Avalyn Pharma Inc. Common Stock
NASDAQ:AVLNMedical - Pharmaceuticals
+$0.52 today
- Market cap
- $1.23B
- Beta
- 0.00
Volume 0.40M
Average 0.51M
AVLN Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Gross Profit history
Currency unavailable · from the income statement
No Gross Profit data reported for this period type.
Gross Profit vs competitors
How AVLN compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $947.34M USD | +214.3% | +36.3% | 83.3% | |
| LTM Mar 2026 | $274.05M USD | +23.4% | +89.5% | 76.0% | |
| LTM Mar 2026 | $111.3M USD | +14.9% | +4.5% | 95.1% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 1.33M SEK | -47.7% | — | 100.0% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding AVLN) | — | +19.2% | +36.3% | 89.2% | |
Competitors are the stored peer set for AVLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Avalyn Pharma Inc. Common Stock
NASDAQ:AVLN
Intrinsic Alpha fair value
Locked
Current Price
$27.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.